Evidence map›Paper›PMID 39392495›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Preclinical evaluation of

Nadine Holzleitner, Meryl Vilangattil, Abir Swaidan, Clara Diaz Garcia-Prada, Marco F Taddio, Pauline Jeanjean, Christine E Mona, Constantin Lapa, Angela Casini, Thomas Günther and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nadine HolzleitnerChair of Pharmaceutical Radiochemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Walther-Meissner-Str. 3, 85748, Garching, Germany. nadine.holzleitner@tum.de.ORCID 0000-0001-8258-3526
Meryl VilangattilDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Abir SwaidanDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Clara Diaz Garcia-PradaDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Marco F TaddioDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Pauline JeanjeanDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Christine E MonaDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA.
Constantin LapaNuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Angela CasiniChair of Pharmaceutical Radiochemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Walther-Meissner-Str. 3, 85748, Garching, Germany.
Thomas GüntherChair of Pharmaceutical Radiochemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Walther-Meissner-Str. 3, 85748, Garching, Germany.
Giuseppe CarlucciDepartment of Molecular and Medical Pharmacology, Biomedical Cyclotron Facility, University of California Los Angeles, 780 Westwood Plaza, Los Angeles, CA, 90024, USA. GCarlucci@mednet.ucla.edu.ORCID 0000-0001-7494-335X

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Bayerisch-Kalifornischen Hochschulzentrum 4 [2022-2]NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

The recently developed metabolically more stable minigastrin derivative, DOTA-CCK-66, displayed promising preclinical data when labeled either with

methodsTreatment studies were performed (3 groups, n = 5, AR42J tumor-bearing 394-NOD SCID mice). Control group animals were injected with [

resultsUpon treatment, an initial decline in tumor volume, followed by a significantly delayed tumor growth of treated cohorts, was observed. Mean survival of

conclusionWe demonstrated a substantial therapeutic efficacy of

Indexed as

ActiniumAlpha ParticlesGastrinsThyroid NeoplasmsAnimalsCell Line, TumorFemaleHumansMicePositron Emission Tomography Computed TomographyRadiopharmaceuticalsTissue DistributionActiniumActinium-225GastrinsminigastrinRadiopharmaceuticalsActinium-225CCK-2RMTCTargeted Alpha Therapy (TAT)

Identifiers

PMID39392495
PMCPMC11732879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.